BBIO Earnings Date 2026
BridgeBio Pharma Inc earnings schedule and quarterly results
Next Earnings Date
TBD
Current Stock Price
$76.65
+0.10% today
Earnings Metrics
EPS (TTM)
$-2.88
P/E Ratio
-26.6
Revenue Growth
2285.3%
Market Cap
$13.2B
Earnings History
| Quarter | EPS | Revenue | Net Income |
|---|---|---|---|
| Q4 2024 | $-2.88 | $0.22B | $-0.54B |
| Q4 2023 | $-3.95 | $0.01B | $-0.65B |
Trading Around BBIO Earnings
Before Earnings
- Review analyst expectations and consensus estimates
- Check options implied volatility for expected move
- Consider historical earnings surprises
- Monitor pre-announcement guidance
After Earnings
- Compare actual results to estimates
- Listen to the earnings call for guidance
- Watch for analyst rating changes
- Monitor institutional buying/selling
Get Full BBIO Analysis
DCF valuation, AI insights, and institutional ownership data
Frequently Asked Questions
When is BBIO next earnings date?
BBIO (BridgeBio Pharma Inc) has not yet announced its next earnings date. Check back for updates on the upcoming earnings schedule.
What is BBIO earnings per share (EPS)?
BBIO's current earnings per share (EPS) is $-2.88. With a P/E ratio of -26.6, the market values each dollar of earnings at $-26.6.
How often does BBIO report earnings?
Like most publicly traded US companies, BBIO (BridgeBio Pharma Inc) reports earnings quarterly, typically within 4-6 weeks after each fiscal quarter ends. The company holds an earnings call to discuss results with analysts.
What time does BBIO report earnings?
BBIO typically reports earnings either before market open (BMO) or after market close (AMC). The exact time is usually announced a few days before the earnings date. Check the investor relations page for specific timing.
How has BBIO performed in recent earnings?
In the most recent quarter (Q4 2024), BBIO reported EPS of $-2.88 on revenue of $0.22B.
What do analysts expect for BBIO earnings?
Analyst expectations for BBIO earnings can vary. The company has shown positive revenue growth of 2285.3%. View the full analyst ratings page for detailed expectations.